MX340822B - Formulaciones para suministro oral de adsorbentes en el intestino. - Google Patents

Formulaciones para suministro oral de adsorbentes en el intestino.

Info

Publication number
MX340822B
MX340822B MX2012009728A MX2012009728A MX340822B MX 340822 B MX340822 B MX 340822B MX 2012009728 A MX2012009728 A MX 2012009728A MX 2012009728 A MX2012009728 A MX 2012009728A MX 340822 B MX340822 B MX 340822B
Authority
MX
Mexico
Prior art keywords
formulation
adsorbents
gut
formulations
oral delivery
Prior art date
Application number
MX2012009728A
Other languages
English (en)
Other versions
MX2012009728A (es
Inventor
De Gunzburg Jean
Lescure François
Original Assignee
Da Volterra *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra * filed Critical Da Volterra *
Publication of MX2012009728A publication Critical patent/MX2012009728A/es
Publication of MX340822B publication Critical patent/MX340822B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una formulación para el suministro retardado y controlado de un adsorbente en el intestino delgado de mamíferos. La formulación incluye una carragenina y un adsorbente, tal como carbón vegetal activado. La invención además se refiere a usos de esta formulación, en particular a usos farmacéuticos. En una modalidad, la formulación se usa para eliminar o reducirlos efectos colaterales en el intestino, en particular en el colon, de agentes farmacéuticos que se administran como un tratamiento para un trastorno, pero que tienen efectos colaterales cuando alcanzan el íleon final, el intestino ciego o el colon.
MX2012009728A 2010-02-23 2011-02-23 Formulaciones para suministro oral de adsorbentes en el intestino. MX340822B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305179 2010-02-23
PCT/EP2011/052682 WO2011104275A1 (en) 2010-02-23 2011-02-23 Formulations for oral delivery of adsorbents in the gut

Publications (2)

Publication Number Publication Date
MX2012009728A MX2012009728A (es) 2012-11-29
MX340822B true MX340822B (es) 2016-07-26

Family

ID=42357439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009728A MX340822B (es) 2010-02-23 2011-02-23 Formulaciones para suministro oral de adsorbentes en el intestino.

Country Status (23)

Country Link
US (4) US9968562B2 (es)
EP (1) EP2538930B1 (es)
JP (1) JP5645975B2 (es)
KR (1) KR101820374B1 (es)
CN (1) CN102869351B (es)
AU (1) AU2011219788B2 (es)
BR (1) BR112012021275B1 (es)
CA (1) CA2790811C (es)
CY (1) CY1117869T1 (es)
ES (1) ES2586135T3 (es)
HK (1) HK1180233A1 (es)
HR (1) HRP20160834T1 (es)
HU (1) HUE029299T2 (es)
IL (1) IL221542A (es)
LT (1) LT2538930T (es)
MX (1) MX340822B (es)
PL (1) PL2538930T3 (es)
PT (1) PT2538930T (es)
RS (1) RS54991B1 (es)
RU (2) RU2012140421A (es)
SI (1) SI2538930T1 (es)
WO (1) WO2011104275A1 (es)
ZA (1) ZA201207068B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586135T3 (es) * 2010-02-23 2016-10-11 Da Volterra Formulaciones para el suministro oral de adsorbentes en el intestino
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
CN102432737B (zh) * 2011-09-07 2015-02-25 张绍国 一种缓释肠溶丙烯酸树脂乳胶液及其制法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
CN111053759A (zh) * 2012-09-21 2020-04-24 辉凌公司 药物组合物
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US9682101B2 (en) 2013-03-25 2017-06-20 Ferring B.V. Composition for the treatment of disease
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
CN108135927A (zh) * 2015-10-06 2018-06-08 达·沃尔泰拉公司 梭菌属细菌的致病性或毒力的抑制或降低
CN108348546A (zh) * 2015-10-26 2018-07-31 第三共株式会社 用于递送至大肠或下部分小肠的多孔材料制剂
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) * 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601745B (zh) * 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
KR101884520B1 (ko) * 2016-07-29 2018-08-02 한국식품연구원 벤토나이트를 유효성분으로 포함하는 염증성 장 질환의 예방 또는 치료용 약학적 조성물
KR102106477B1 (ko) * 2017-01-12 2020-05-06 차장옥 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TWI823954B (zh) 2018-06-20 2023-12-01 瑞典商艾爾比瑞歐公司 奧德維希百(odevixibat)之結晶修飾物
US20210290741A1 (en) 2018-08-05 2021-09-23 Da Volterra Compositions for the treatment of graft versus host disease
CA3106429A1 (en) 2018-08-05 2020-02-13 Da Volterra Method for improving anticancer agent efficacy
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
EP4125847A4 (en) 2020-04-03 2024-06-19 Lpoxy Therapeutics, Inc. ENTERAL AEROBIZATION THERAPY
RU2747401C1 (ru) * 2020-06-22 2021-05-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный университет" Способ получения фармацевтических лекарственных форм на основе сополимеров метилметакрилата
WO2022084550A1 (en) 2020-10-23 2022-04-28 Da Volterra Compositions for use in the treatment or prevention of dysbiosis
WO2022090433A1 (en) 2020-10-30 2022-05-05 Da Volterra Method for the manufacture of an adsorbent formulation
WO2022101267A2 (en) 2020-11-12 2022-05-19 Da Volterra Compositions for delivery of an adsorbent
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut
KR20240095216A (ko) 2021-09-29 2024-06-25 엘폭시 세라퓨틱스 인코퍼레이티드 장 호기화 요법

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917821A (en) 1973-10-23 1975-11-04 Milton Manes Palatable activated carbon
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5542210A (en) * 1978-09-12 1980-03-25 Koichi Ogawa Special activated carbon
JPS62168540A (ja) * 1986-01-21 1987-07-24 Freunt Ind Co Ltd 被覆方法
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
WO1988001506A1 (en) * 1986-08-28 1988-03-10 Thomas Ko Sai Ying Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
JPH03120227A (ja) 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3338119B2 (ja) * 1993-04-14 2002-10-28 呉羽化学工業株式会社 抗糖尿病剤
US5827497A (en) 1996-08-14 1998-10-27 Mayo Foundation For Medical Education And Research Charcoal-radionuclide agents for measurement of gastrointestinal transit
FR2780052B1 (fr) 1998-06-23 2000-07-21 Ceca Sa Agglomerats a base de charbon actif leur procede de preparation et leur utilisation comme agents d'adsorption
JP2004507339A (ja) 2000-04-21 2004-03-11 ウォーターヴィジョンズ　インターナショナル，　インコーポレイティッド 膨張性物質を有する複合材料の形成
EP1370672A1 (en) * 2001-01-19 2003-12-17 Rhodia Chimie Process for producing carrageenan with reduced amount of insoluble material
CA2344910C (en) * 2001-04-23 2009-07-07 Kureha Chemical Industry Co., Ltd. Method for treating renal disease, and pharmaceutical composition for treating renal disease
EP1306128A1 (en) * 2001-10-29 2003-05-02 Tenaxis Gmbh Sorptive composite materials
JP4486300B2 (ja) 2002-07-25 2010-06-23 ユニ・チャーム株式会社 吸収性物品のトップシート
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP3585043B2 (ja) * 2003-01-22 2004-11-04 メルク・ホエイ株式会社 医薬用吸着剤及びその製法
JPWO2004096243A1 (ja) * 2003-04-25 2006-07-13 亘起物産有限会社 便秘予防および改善剤
GB2405343A (en) 2003-08-29 2005-03-02 Johnson & Johnson Medical Ltd Charcoal Wound Dressings
JP4409245B2 (ja) * 2003-10-20 2010-02-03 株式会社荏原製作所 耐食性及び耐摩耗性を有する被覆用合金を用いた装置
CN1615908B (zh) 2003-10-22 2011-09-28 株式会社吴羽 口服给药用吸附剂、以及肾病治疗或预防剂、和肝病治疗或预防剂
TWI370012B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
WO2005120458A1 (ja) 2004-06-07 2005-12-22 Kureha Corporation 乾燥形態経口摂取用組成物及び用時調製形ゲル状経口摂取用組成物
WO2006044805A2 (en) 2004-10-15 2006-04-27 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP1883396B1 (en) 2005-05-18 2013-07-03 DA Volterra Colonic delivery of adsorbents
CA2628977C (en) * 2005-11-07 2018-04-17 Russell M. Jaffe Composition for regulating intestinal disorders comprising selenium, prebiotics, phosphatides and flavonols, and methos of use thereof
US8557274B2 (en) * 2005-12-06 2013-10-15 Purdue Research Foundation Slowly digesting starch and fermentable fiber
US7749497B2 (en) 2005-12-06 2010-07-06 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
DE102005062160A1 (de) * 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080089943A1 (en) * 2006-08-17 2008-04-17 Xavier Frapaise Use of adsorbent carbon microspheres to treat gastroesophogeal reflux disease
DE202006016898U1 (de) * 2006-10-12 2007-11-22 BLüCHER GMBH Hochleistungsadsorbentien auf der Basis von Aktivkohle mit hoher Mikroporosität
JP2010510196A (ja) * 2006-11-17 2010-04-02 ダ・ボルテラ オイドラギット被覆を施した亜鉛／ペクチンビーズを使用する結腸送達
WO2008073517A1 (en) * 2006-12-07 2008-06-19 Ehrenpreis Eli D Treatment for intestinal gas, bloating, microscopic colitis and traveler's diarrhea using colloidal bismuth subcitrate
US20100036002A1 (en) * 2006-12-26 2010-02-11 Medrx Co., Ltd. Pharmaceutical composition comprising porous dry matrix
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US20090148538A1 (en) * 2007-10-12 2009-06-11 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres to treat pouchitis
DE102008014109A1 (de) 2008-03-13 2009-09-17 Bayer Animal Health Gmbh Suspensionsformulierung für Kohlenstoff-Adsorbentien
KR20100001892A (ko) 2008-06-27 2010-01-06 주식회사 에코비젼 핵입자를 함유하는 질산화 미생물의 그래뉼 및 질산화미생물의 그래뉼화 촉진방법
FR2950252B1 (fr) 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
ES2586135T3 (es) * 2010-02-23 2016-10-11 Da Volterra Formulaciones para el suministro oral de adsorbentes en el intestino

Also Published As

Publication number Publication date
US20180369156A1 (en) 2018-12-27
EP2538930A1 (en) 2013-01-02
EP2538930B1 (en) 2016-06-15
CY1117869T1 (el) 2017-05-17
US10052288B2 (en) 2018-08-21
MX2012009728A (es) 2012-11-29
RU2681315C2 (ru) 2019-03-06
RU2012140421A (ru) 2014-03-27
BR112012021275A2 (pt) 2016-10-25
US20130052269A1 (en) 2013-02-28
HK1180233A1 (zh) 2013-10-18
JP5645975B2 (ja) 2014-12-24
US20220087945A1 (en) 2022-03-24
BR112012021275B1 (pt) 2021-07-27
ES2586135T3 (es) 2016-10-11
AU2011219788B2 (en) 2015-05-14
ZA201207068B (en) 2013-05-29
IL221542A (en) 2017-06-29
RS54991B1 (sr) 2016-11-30
CA2790811C (en) 2017-12-05
US9968562B2 (en) 2018-05-15
RU2016147198A (ru) 2018-06-01
AU2011219788A1 (en) 2012-09-06
WO2011104275A1 (en) 2011-09-01
CN102869351B (zh) 2015-07-01
US20170296478A1 (en) 2017-10-19
HUE029299T2 (en) 2017-02-28
PL2538930T3 (pl) 2016-11-30
KR101820374B1 (ko) 2018-01-19
CN102869351A (zh) 2013-01-09
PT2538930T (pt) 2016-08-05
KR20130044214A (ko) 2013-05-02
HRP20160834T1 (hr) 2016-09-23
JP2013520467A (ja) 2013-06-06
LT2538930T (lt) 2016-09-26
CA2790811A1 (en) 2011-09-01
US11202761B2 (en) 2021-12-21
RU2016147198A3 (es) 2018-06-01
SI2538930T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
EP3904502A3 (en) Compositions and methods
WO2009008001A3 (en) Inhalation device
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
WO2013138702A3 (en) Methods for predicting gastrointestinal immune - related adverse events (gi-irae) in patients treated with co - stimulatory pathway modulators
MY153408A (en) Novel methods
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
IN2015DN03219A (es)
IN2014MN00333A (es)
IL201479A (en) Use of tapentadol for the preparation of pain medication
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2014044794A3 (en) Pharmaceutical composition
WO2012174158A3 (en) Administration of benzodiazepine
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016003490A (es) Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune.
NZ592049A (en) Compositions and methods for the treatment of bowel diseases with granulated mesalamine
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX353649B (es) Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.
WO2012135848A3 (en) Melatonin-based treatment and diagnosis of bile duct disease
EP2682101A3 (en) Inhalation Compositions Comprising Glucose Anhydrous

Legal Events

Date Code Title Description
FG Grant or registration